Please login to the form below

Not currently logged in
Email:
Password:

King's profits hit by generic competition

King Pharmaceuticals' second-quarter profit fell 53 per cent to $18m, as generic sales reduced Skelaxin's (metaxalone) revenue by 95 per cent

King Pharmaceuticals' second-quarter profit fell 53 per cent to $18m, or 7 cents per share, from $37.9m or 15 cents per share a year ago as generic sales reduced revenue of its muscle relaxant Skelaxin (metaxalone) by 95 per cent.

Revenue from Skelaxin in the three-month period was just $5m due to the introduction of two unbranded competitors early in the second quarter. A year before it had generated $102m.

Skelaxin came off patent in January 2009 and two companies began selling low-cost generic versions early in the second quarter.

Total branded drug sales in the period ending June 30 reached $162m compared with $275m in the year before. Overall revenue for the second quarter decreased 17 per cent to $371m but exceeded analysts' forecasts of $361m. 

Its pain drug Embeda (morphine sulfate and naltrexone hydrochloride) is showing continued growth since it launched in September 2010 and reaped $15m during the second quarter. But falls in sales were seen with the bleeding-control drug Thrombin-JMI (Thrombin Topical Bovine Origin), Ling's painkiller Avinza (morphine sulfate) and its Flector (diclofenac) painkiller patch.

CEO Brian Markison noted, however, that regulatory filings for both Remoxy (oxycodone) and Acurox (oxycodone HCI/niacin) "remain on track for FDA submission with Remoxy scheduled for the end of this year and Acurox scheduled for the first quarter of 2011."

10th August 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...